

Encarna Adrover

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1761759/publications.pdf>

Version: 2024-02-01

13
papers

719
citations

840119

11
h-index

1125271

13
g-index

13
all docs

13
docs citations

13
times ranked

1236
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 805-814.	3.0	208
2	Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 2200-2210.	13.9	169
3	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Oncology</i> , The, 2011, 12, 369-376.	5.1	73
4	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3788-3795.	0.8	56
5	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983386.	1.4	39
6	Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma. <i>Modern Pathology</i> , 2011, 24, 201-208.	2.9	37
7	Tumor-Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1298-1299.	0.8	32
8	¹⁸ F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017, 23, 1432-1441.	3.2	32
9	Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. <i>Human Pathology</i> , 2014, 45, 504-512.	1.1	26
10	Critically short telomeres and toxicity of chemotherapy in early breast cancer. <i>Oncotarget</i> , 2017, 8, 21472-21482.	0.8	14
11	Prognostic Implications of HER-2 Status in Steroid Receptorâ€“Positive, Lymph Nodeâ€“Negative Breast Carcinoma. <i>American Journal of Clinical Pathology</i> , 2007, 127, 780-786.	0.4	13
12	Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 433-441.	1.1	11
13	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. <i>Scientific Reports</i> , 2020, 10, 7741.	1.6	9